Back to results
US 11,737,993 B2Granted
Multiple myeloma treatment
AssigneeVanda Pharmaceuticals Inc.
InventorsMihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Life of this patent
Estimating the term…
Abstract
The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Claims13
A method of treating a patient suffering from multiple myeloma (MM), the method comprising:
- determining or having determined, from a biological sample obtained from the patient's body, that a level of expression of one or more gene selected from a group consisting of:
- AURKB, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1 is indicative of overexpression;
- and
- administering to the patient an effective amount of trichostatin A (TSA),
- wherein the effective amount is between about 0.01 mg/kg/day and about 100 mg/kg/day and effective to decrease expression of the one or more gene.
2 more elements
In a method of treating multiple myeloma (MM) with trichostatin A (TSA), the improvement comprising:
- selecting for treatment with between about 0.01 mg/kg and about 100 mg/kg per day of TSA a patient determined to overexpress at least one gene selected from a group consisting of:
- AURKB, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.
Dependencies are inferred from the claim text.